GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND A METHOD OF ITS PREPARATION Russian patent published in 2023 - IPC C07D401/14 C07D405/14 C07D413/14 A61K31/4188 A61K31/4439 A61P1/16 A61P3/00 A61P9/00 A61P25/28 

FIELD: pharmaceuticals.

SUBSTANCE: invention relates to a new compound of formula 1, its isomer or pharmaceutically acceptable salt, where A represents -(CH₂)_m- or -O-, where m is an integer with a value from 1 to 3; R₁ is (4–6 membered heterocycloalkyl containing one O)C_1-6alkyl heteroatom, or (5-membered heteroaryl containing one or more heteroatoms selected from N and O)C_1-6alkyl; R₂ is independently either hydrogen or halogen; R₃ is hydrogen; R₄ is independently either hydrogen, halogen, C_1-6alkyl substituted with halogen, or a nitrile group; n is an integer with the value from 1 to 4, where if n is an integer with the value from 2 to 4, each of R₂, R₃ and R₄ may be the same or different from each other; Z₁, Z₂, Z₃ and Z ₇ are CH; and Z₄, Z₅ or Z₆ are each independently CH, CF, CCl, CBr or CI; where heterocycloalkyl or heteroaryl is either unsubstituted or substituted with C_1-6alkyl. The invention also relates to a pharmaceutical composition containing such a compound and a method of producing such a compound. The technical result of the invention is to obtain a new compound with the activity of a GLP-1 agonist.

[Formula 1]

EFFECT: invention can be used as an agent for the treatment or prevention of various metabolic diseases such as obesity, diabetes and hyperlipidemia.

13 cl, 1 tbl, 37 ex